What Could IPO and M&A Markets Look Like in the Coming Quarter?

What could the acquisition of TearScience and Kala Pharmaceuticals mean for the broader M&A and IPO activity? We ask Andrew Gitkin, managing director and head of West Coast biotechnology investment banking at Piper Jaffray.